Profile data is unavailable for this security.
About the company
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NYMOZARFEX, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company also has a patent portfolio covering its marketed products, its investigational drug as well as other therapeutic and diagnostic indications. It also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Its products also include NicAlert and TobacAlert. NicAlert is a simple test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample. TobacAlert is a home test that provides a quick, accurate, on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke.
- Revenue in USD (TTM)0.00
- Net income in USD-8.84m
- Incorporated2015
- Employees3.00
- LocationNymox Pharmaceutical CorpSt. Laurent9900 Cavendish Blvd Suite 306SAINT-LAURENT H4M 2V2CanadaCAN
- Websitehttps://nymox.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tenax Therapeutics Inc | 0.00 | -12.57m | 11.18m | 5.00 | -- | 0.7236 | -- | -- | -22.35 | -22.35 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -101.95 | -199.16 | -113.79 | -285.64 | -- | -- | -- | -- | -- | -95.94 | 0.0305 | -- | -- | -- | 30.21 | -- | -- | -- |
| BioRestorative Therapies Inc | 174.10k | -8.00m | 11.42m | 11.00 | -- | 1.06 | -- | 65.58 | -1.22 | -1.22 | 0.029 | 1.56 | 0.0118 | -- | 6.65 | 15,827.27 | -54.42 | -192.11 | -68.75 | -329.32 | 47.45 | -- | -4,597.79 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -12.75m | 11.43m | 29.00 | -- | -- | -- | -- | -3.36 | -3.36 | 0.00 | -0.6642 | 0.00 | -- | -- | 0.00 | -223.03 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Dominari Holdings Inc | 9.51m | -22.02m | 11.49m | 26.00 | -- | 0.2698 | -- | 1.21 | -3.85 | -3.85 | 1.67 | 6.78 | 0.1629 | -- | 2.60 | 365,730.80 | -37.71 | -26.82 | -39.96 | -27.45 | -- | -- | -231.55 | -3,353.52 | -- | -5.05 | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Indaptus Therapeutics Inc | 0.00 | -15.75m | 11.73m | 7.00 | -- | 1.60 | -- | -- | -1.86 | -1.86 | 0.00 | 0.7209 | 0.00 | -- | -- | 0.00 | -108.73 | -66.55 | -126.30 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| GlucoTrack Inc | 0.00 | -12.05m | 11.79m | 6.00 | -- | -- | -- | -- | -2.42 | -2.42 | 0.00 | -0.6004 | 0.00 | -- | -- | 0.00 | -251.32 | -94.01 | -493.89 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | -- | -- | -- | -- | -60.02 | -- | -- | -- |
| Sensei Biotherapeutics Inc | 0.00 | -29.67m | 11.85m | 28.00 | -- | 0.2267 | -- | -- | -1.18 | -1.18 | 0.00 | 2.08 | 0.00 | -- | -- | 0.00 | -39.73 | -47.03 | -42.67 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0232 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| Jaguar Health Inc | 10.19m | -35.67m | 11.92m | 49.00 | -- | 0.5973 | -- | 1.17 | -41.34 | -41.34 | 6.62 | 2.48 | 0.1793 | 0.231 | 7.56 | 207,857.10 | -63.73 | -95.29 | -110.34 | -163.54 | 79.79 | 67.28 | -355.51 | -522.28 | 1.60 | -3.45 | 0.6333 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| NKGen Biotech Inc | 0.00 | -88.25m | 12.08m | 63.00 | -- | -- | -- | -- | -3.74 | -3.74 | 0.00 | -2.71 | 0.00 | -- | -- | 0.00 | -480.25 | -- | -- | -- | -- | -- | -- | -- | -- | -0.4822 | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -28.90m | 12.09m | 42.00 | -- | 0.7827 | -- | -- | -1.31 | -1.31 | 0.00 | 0.5206 | 0.00 | -- | -- | 0.00 | -101.76 | -- | -136.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
| Nymox Pharmaceutical Corp | 0.00 | -8.84m | 12.16m | 3.00 | -- | -- | -- | -- | -0.0966 | -0.0966 | 0.00 | -0.0339 | 0.00 | -- | -- | -- | -785.44 | -306.39 | -- | -749.37 | -- | -- | -- | -43,683.47 | -- | -157.57 | -- | -- | -- | -- | -34.49 | -- | -39.16 | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 12.40m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Cell Source Inc | 0.00 | -6.45m | 12.58m | -- | -- | -- | -- | -- | -0.1627 | -0.1627 | 0.00 | -0.413 | 0.00 | -- | -- | -- | -1,300.91 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -5.14 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 15.22k | -13.80m | 12.69m | 12.00 | -- | 1.20 | -- | 834.08 | -0.8373 | -0.8373 | 0.0008 | 0.3565 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Aspira Women's Health Inc | 8.92m | -15.95m | 13.04m | 64.00 | -- | -- | -- | 1.46 | -1.45 | -1.45 | 0.801 | -0.2892 | 1.53 | 15.11 | 5.79 | 139,421.90 | -273.16 | -110.58 | -3,758.30 | -151.88 | 57.84 | 45.23 | -178.80 | -334.08 | 0.5542 | -17,354.00 | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Alterola Biotech Inc | 0.00 | -2.06m | 13.14m | 1.00 | -- | -- | -- | -- | -0.0017 | -0.0017 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -32.46 | -- | -46.53 | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | -- | -- | -14.64 | -- | -- | -- |
Data as of Oct 08 2024. Currency figures normalised to Nymox Pharmaceutical Corp's reporting currency: US Dollar USD
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| First Citizens Bank (Private Banking)as of 30 Jun 2024 | 35.10k | 0.00% |
| Cubic Asset Management LLCas of 31 Mar 2024 | 10.00k | 0.00% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.69k | 0.00% |
| BlackRock Japan Co. Ltd.as of 20 Sep 2022 | 0.00 | 0.00% |
| State of Wisconsin Investment Boardas of 31 Dec 2022 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
